Alnylam Gene Silencing Candidate Reduces Toxic Huntingtin Protein by Over Sixty Percent

By Jason Mast and Elaine Chen · STAT News · 2026-10-23

Alnylam Gene Silencing Candidate Reduces Toxic Huntingtin Protein by Over Sixty Percent

STAT News reports that Alnylam Pharmaceuticals achieved significant gene knockdown in a small-scale trial for its experimental Huntington’s disease therapy. The drug, known as brezosiran, targets the genetic drivers of the condition to lower mutant protein levels in the spinal fl

STAT News reports that Alnylam Pharmaceuticals achieved significant gene knockdown in a small-scale trial for its experimental Huntington’s disease therapy. The drug, known as brezosiran, targets the genetic drivers of the condition to lower mutant protein levels in the spinal fl